Skip to main content
SpringerLink
Log in
Book cover

Pathology of Female Cancers pp 37–46Cite as

Current Concept of Precancerous and Early Stage of Serous Ovarian Carcinoma

  • Chapter
  • First Online:

Abstract

Two types of ovarian serous carcinomas are recognized including high-grade (HGSC) and low-grade serous carcinoma (LGSC). These fundamentally differ in terms of histology, phenotype, underlying genetics, carcinogenetic mechanisms, and biological behavior. The vast majority of them are HGSC.Recent evidence strongly suggests most cases considered as ovarian HGSC according to the classical definition are secondary involvement of tubal HGSC, either in the form of non-invasive or invasive HGSC. Serous tubal intraepithelial carcinoma (STIC) is a non-invasive tubal HGSC and is detected mostly at the fimbriated end. Tumor protein (TP)53 mutations are present in most HGSC cases and BRCA network dysregulation in 50%. More than 80% of HGSC patients present with advanced stage disease (Stage III/IV). HGSC patients have poor prognosis: although most HGSC responds to platinum/taxol chemotherapy after debulking surgery, the majority of cases show recurrence leading to death.LGSC often coexists with and is thought to arise from serous borderline tumor. About 40%–60% of LGSC harbor somatic mutations in KRAS and BRAF. TP53 or BRCA mutation is rare in LGSC. LGSC confined to the ovary has excellent prognosis with surgical therapy alone; however, invasive LGSC is less responsive to current platinumbased chemotherapy regimens than HGSC.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35.

    Article  CAS  PubMed  Google Scholar 

  2. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–49.

    Article  PubMed  Google Scholar 

  3. The Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology. Patient Annual Report for 2015. Acta Obsterica et Gynaecololgica Japonica 2017;69:1211.

    Google Scholar 

  4. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC Press; 2014.

    Google Scholar 

  5. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504.

    Article  PubMed  Google Scholar 

  6. Takeuchi T, Ohishi Y, Imamura H, Aman M, Shida K, Kobayashi H, Kato K, Oda Y. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma. Am J Surg Pathol. 2013;37:1091–9.

    Article  PubMed  Google Scholar 

  7. Cuatrecasas M, Catasus L, Palacios J, Prat J. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol. 2009;33:556–67.

    Article  PubMed  Google Scholar 

  8. Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. Int J Gynecol Pathol. 2012;31:499–506.

    Article  CAS  PubMed  Google Scholar 

  9. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694–706.

    Article  CAS  PubMed  Google Scholar 

  10. Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625–36.

    Article  CAS  PubMed  Google Scholar 

  11. O’Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773–9.

    Article  PubMed  Google Scholar 

  12. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267–82.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol. 2009;115:209–14.

    Article  CAS  PubMed  Google Scholar 

  14. Seidman JD, Horkayne-Szakaly I, Cosin JA, Ryu HS, Haiba M, Boice CR, Yemelyanova AV. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol. 2006;103:703–8.

    Article  PubMed  Google Scholar 

  15. Motohara T, Tashiro H, Miyahara Y, Sakaguchi I, Ohtake H, Katabuchi H. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma. Cancer Sci. 2010;101:1550–6.

    Article  CAS  PubMed  Google Scholar 

  16. Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. Gynecol Oncol. 2012;125:655–60.

    Article  PubMed  Google Scholar 

  17. Eisenkop SM, Spirtos NM, Lin WC. “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol. 2006;103:329–35.

    Article  PubMed  Google Scholar 

  18. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353–7.

    Article  CAS  PubMed  Google Scholar 

  19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.

    Article  CAS  Google Scholar 

  20. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Kobel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517–25.

    PubMed  CAS  Google Scholar 

  21. Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, Yamanoi K, Abiko K, Yoshioka Y, Hamanishi J, Yamaguchi K, Baba T, Koshiyama M, Enomoto T, Okamoto A, Murphy SK, Mori S, Mikami Y, Minamiguchi S, Konishi I. Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am J Pathol. 2016;186:1103–13.

    Article  CAS  PubMed  Google Scholar 

  22. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001;22:255–88.

    PubMed  CAS  Google Scholar 

  23. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451–6.

    Article  CAS  PubMed  Google Scholar 

  24. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230–6.

    Article  PubMed  Google Scholar 

  25. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–9.

    Article  PubMed  Google Scholar 

  26. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283–9.

    Article  CAS  PubMed  Google Scholar 

  27. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985–90.

    Article  PubMed  Google Scholar 

  28. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58–64.

    Article  CAS  PubMed  Google Scholar 

  29. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol. 2009;33:376–83.

    Article  PubMed  Google Scholar 

  30. Tang S, Onuma K, Deb P, Wang E, Lytwyn A, Sur M, Daya D. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol. 2012;31:103–10.

    Article  PubMed  Google Scholar 

  31. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407–16.

    Article  PubMed  Google Scholar 

  32. Gilks CB, Irving J, Kobel M, Lee C, Singh N, Wilkinson N, McCluggage WG. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Am J Surg Pathol. 2015;39:357–64.

    Article  PubMed  Google Scholar 

  33. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160–5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408–17.

    Article  CAS  PubMed  Google Scholar 

  35. Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih Ie M. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010;34:829–36.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih Ie M. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol. 2016;29:1254–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology. 2015;67:331–7.

    Article  PubMed  Google Scholar 

  38. Prat J. Abridged republication of FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer. 2015;121(19):3452–4.

    Article  PubMed  Google Scholar 

  39. Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014;65:149–54.

    Article  PubMed  Google Scholar 

  40. McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2015;28:1101–22.

    Article  PubMed  Google Scholar 

  41. Prat J. Ovarian, fallopian tube and peritoneal cancer staging: rationale and explanation of new FIGO staging 2013. Best Pract Res Clin Obstet Gynaecol. 2015;29:858–69.

    Article  PubMed  Google Scholar 

  42. Gilks CB, Miller D. Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come. Gynecol Oncol. 2013;129:443–4.

    Article  PubMed  Google Scholar 

  43. McAlpine JN, Tone AA, Hanley GE. Opportunistic salpingectomy: we chose to act, not wait. J Obstet Gynaecol. 2016;38:425–7.

    Google Scholar 

  44. Kho RM, Wechter ME. Operative outcomes of opportunistic bilateral salpingectomy at the time of benign hysterectomy in low-risk premenopausal women: a systematic review. J Minim Invasive Gynecol. 2017;24:218–29.

    Article  PubMed  Google Scholar 

  45. Hanley GE, McAlpine JN, Kwon JS, Mitchell G. Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract. 2015;2:5.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Meserve EE, Brouwer J, Crum CP. Serous tubal intraepithelial neoplasia: the concept and its application. Mod Pathol. 2017;30:710.

    Article  PubMed  Google Scholar 

  47. Nafisi H, Ghorab Z, Ismill N, Dube V, Plotkin A, Han G, Cesari M, Lu FI, Saad R, Khalifa M, Nofech-Mozes S. Immunophenotypic analysis in early Mullerian serous carcinogenesis. Int J Gynecol Pathol. 2015;34:424–36.

    Article  CAS  PubMed  Google Scholar 

  48. Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, Shih Ie M, Kurman RJ. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011;35:1766–75.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Li RF, Ronnett BM, Seidman JD, Yemelyanova A, Shih Ie M, Shaw PA, Soslow RA, Kurman RJ. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31:243–53.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14–21.

    Article  PubMed  Google Scholar 

  51. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1–9.

    Article  PubMed  Google Scholar 

  52. Jarboe EA, Miron A, Carlson JW, Hirsch MS, Kindelberger D, Mutter GL, Crum CP, Nucci MR. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol. 2009;28:308–15.

    Article  PubMed  Google Scholar 

  53. Rabban JT, Vohra P, Zaloudek CJ. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia. Am J Surg Pathol. 2015;39:35–51.

    Article  PubMed  Google Scholar 

  54. Stewart CJ, Leung YC, Whitehouse A. Fallopian tube metastases of non-gynaecological origin: a series of 20 cases emphasizing patterns of involvement including intra-epithelial spread. Histopathology. 2012;60:E106–14.

    Article  PubMed  Google Scholar 

  55. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008;109:168–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012;127:88–93.

    Article  CAS  PubMed  Google Scholar 

  57. Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K. Incidence and characteristics of unsuspected neoplasia discovered in high-risk women undergoing risk reductive bilateral Salpingooophorectomy. Int J Gynecol Cancer. 2016;26:1415–20.

    Article  PubMed  Google Scholar 

  58. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127–32.

    Article  PubMed  Google Scholar 

  59. Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014;38:729–42.

    Article  PubMed  Google Scholar 

  60. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6:e1000114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Bell DA. Low-grade serous tumors of ovary. Int J Gynecol Pathol. 2014;33:348–56.

    Article  PubMed  Google Scholar 

  62. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012;118:3087–94.

    Article  PubMed  Google Scholar 

  63. Hannibal CG, Vang R, Junge J, Frederiksen K, Kurman RJ, Kjaer SK. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. Gynecol Oncol. 2017;144:174–80.

    Article  PubMed  Google Scholar 

  64. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–8.

    Article  PubMed  Google Scholar 

  65. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14:134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915–8.

    Article  CAS  PubMed  Google Scholar 

  68. Maniar KP, Wang Y, Visvanathan K, Shih Ie M, Kurman RJ. Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases. Am J Surg Pathol. 2014;38:743–55.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Barcena C, Oliva E. WT1 expression in the female genital tract. Adv Anat Pathol. 2011;18:454–65.

    Article  CAS  PubMed  Google Scholar 

  70. Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Kobel M. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol. 2013;128:371–6.

    Article  CAS  PubMed  Google Scholar 

  71. Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627–35.

    PubMed  Google Scholar 

  72. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001;25:419–32.

    Article  CAS  PubMed  Google Scholar 

  73. Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125–42.

    Article  CAS  PubMed  Google Scholar 

  74. Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol. 2002;26:1129–41.

    Article  PubMed  Google Scholar 

  75. Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, Modan B, Ben-Baruch G. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005;97:780–3.

    Article  PubMed  Google Scholar 

  76. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539–57.

    Article  CAS  PubMed  Google Scholar 

  77. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319–30.

    Article  CAS  PubMed  Google Scholar 

  78. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol. 2003;27:725–36.

    Article  PubMed  Google Scholar 

  79. Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 1998;82:1096–103.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan

    Takako Kiyokawa & Masami Iwamoto

Authors
  1. Takako Kiyokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masami Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takako Kiyokawa .

Editor information

Editors and Affiliations

  1. Department of Pathology, Kawasaki Medical School, Kurashiki, Japan

    Takuya Moriya

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kiyokawa, T., Iwamoto, M. (2018). Current Concept of Precancerous and Early Stage of Serous Ovarian Carcinoma. In: Moriya, T. (eds) Pathology of Female Cancers. Springer, Singapore. https://doi.org/10.1007/978-981-10-8606-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-8606-9_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-8605-2

  • Online ISBN: 978-981-10-8606-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation